Loading...
XNAS
CDXS
Market cap155mUSD
Dec 05, Last price  
1.83USD
1D
3.39%
1Q
-24.38%
Jan 2017
-60.22%
IPO
-86.97%
Name

Codexis Inc

Chart & Performance

D1W1MN
XNAS:CDXS chart
P/E
—
P/S
2.62
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.37%
Rev. gr., 5y
-2.82%
Revenues
59m
-15.39%
12,127,00025,333,00050,478,00082,908,000107,104,000123,865,00088,298,00031,922,00035,307,00041,804,00048,837,00050,024,00060,594,00068,458,00069,056,000104,754,000138,590,00070,143,00059,345,000
Net income
-65m
L-14.38%
-18,671,000-38,977,000-45,127,000-20,289,000-8,541,000-16,550,000-30,857,000-41,303,000-19,071,000-7,581,000-8,558,000-22,996,000-10,878,000-11,935,000-24,010,000-21,279,000-33,592,000-76,240,000-65,276,000
CFO
-49m
L-6.13%
-13,287,000-6,470,000-36,316,000-8,686,000-16,383,000-490,000-11,892,000-22,998,000321,000-433,000-2,701,000-8,763,000-14,094,000-12,560,000-16,464,000-14,267,00011,284,000-52,638,000-49,410,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
URL
https://www.codexis.com/
IPO date
Apr 22, 2010
Employees
248
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT